Vol. 22/No. 4 | OncologyLive

Frontline ICI Therapy Gains Traction Across NSCLC Settings

March 04, 2021

Treatment strategies for patients with advanced-stage non–small cell lung cancer have shifted away from platinum-based doublet chemotherapy and toward combination strategies that include immune checkpoint inhibitors.

Practices Grapple With an Aging Oncology Workforce

February 25, 2021

The COVID-19 pandemic may have stalled some physician retirements, but some experts are predicting an exodus of oncologists within the next 1 or 2 years. Practice managers are working now to mitigate the impact with both formal and informal initiatives.

Findings Suggest Cholesterol Plays a Surprising Role in Pancreatic Cancer

February 24, 2021

Although a majority of pancreatic cancer cells are highly dependent on endogenous biosynthesis of cholesterol, new research from investigators at Fox Chase Cancer Center has demonstrated that some more aggressive pancreatic cancers are completely independent of this process.

Investigators Aim Novel T-Cell Therapy at Solid Tumor Target

February 23, 2021

Clinical Trial Reports

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

Gomella Lauds Breakthroughs in GU Cancers

February 22, 2021

Cover Story

A recent wave of drug approvals for treating prostate cancer in earlier disease states, coupled with genomic advances, may help pave the way for a shift toward handling the malignancy as a chronic condition.

It’s Time to Rethink 4 Unique Cancer Terms

February 20, 2021

From the Editor

When one is dealing with the topic of cancer, its treatment and consequences, language that clinicians and members of the cancer research community use may have an even greater impact.